Promoting precision medicine
Precision medicine, also known as personalized medicine, is a healthcare approach that tailors treatment to each individual’s unique genetic makeup, protein profiles, and other biological markers. By examining a patient’s genetics, physicians can develop personalized treatment plans that improve outcomes, reduce drug costs, and avoid ineffective therapies.
Precision medicine is not a new concept, and is readily available in many hospitals. However, it lacks recognition and many people miss out on the opportunity, not knowing it was even an option. Furthermore, precision medicine still needs evidence and system-level integration before it becomes widely accessible to people, and the lack of recognition is slowing down investment as well as data collection.
Organizations such as Washington Genes to Wellness are working to increase awareness of precision medicine and help more people understand its benefits.
To advance innovation in precision medicine, we are launching a fundraising campaign to support early-stage research by providing funding for ideas that lack initial support. This enables scientists to quickly validate or dismiss new concepts, ensuring resources are focused on the most promising solutions. Both positive and negative results are valuable—negative findings prevent wasted effort, while positive outcomes can drive progress
Supporting the use of biomarkers
Biomarker testing is a crucial step in precision medicine. Biomarker testing provides critical insights into a patient’s cancer, enabling targeted therapies that can improve survivorship and quality of life. However, access to this advanced technology remains limited due to insufficient insurance coverage; in Washington State, coverage is restricted to advanced cancer cases (stages 3 and 4), which in most cases, is unfortunately already too late for precise treatment. Washington Genes to Wellness strongly supports HB1062, which would require insurance coverage for biomarker testing for all stages of cancer. Similar legislation has already been enacted in twenty states, including California, New York, and Arizona. Expanding coverage will ensure all cancer patients have access to the biomarker testing essential for their care.
Rising awareness of radon risks
Radon exposure is a significant risk factor for lung cancer among Washingtonians. As an invisible, colorless, and odorless gas released from rocks and soil, radon levels in Washington State average 7.5 pCi/L—well above the EPA’s recommended action level of 4 pCi/L and ranking 10th nationally. Radon can accumulate indoors, especially in homes, where it may reach dangerous levels. Exposure to high concentrations of radon is a serious health hazard and can lead to fatal outcomes: Radon is the leading cause of lung cancer among non-smokers and is responsible for about 21,000 lung cancer deaths each year in the United States, including an estimated 372 deaths annually in Washington State. Unlike tobacco exposure, radon risks are less widely known but are preventable with proper awareness. Washington Genes to Wellness is committed to educating the public about radon risks and providing resources to help reduce exposure.